Posted by Michael Wonder on 31 Jan 2022
Health Canada authorises Verzenio (abemaciclib) as the first and only CDK4/6 inhibitor for patients with HR+ HER2- high risk early breast cancer
27 January 2022 - Adding Verzenio to endocrine therapy demonstrated a significant and clinically meaningful reduction in the risk of recurrence in patients with hormone receptor positive and human epidermal growth factor 2 negative, node-positive, high risk early breast cancer and a Ki-67 score of ≥20%.
Lilly Canada is pleased to announce that Health Canada has authorized Verzenio (abemaciclib) (tablets), in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ≥20%.
